Abstract:Abstract Melasma is a common pigmentary disorder causing considerable cosmetic disfigurement and psychological distress. Treatment of melasma remains a challenge despite the availability of several therapeutic agents, due to its refractory and recurrent nature. Triple combination cream (TCC) consisting of hydroquinone (4%), tretinoin (0.05%) and fluocinolone acetonide (0.01%) is considered to be the first-line therapy for melasma. Ablative fractional lasers have been reported to be effective. We evaluated the effectiveness and safety of fractional ablative CO2 and TCC in melasma in a split-face randomized control study. Clinically diagnosed adult patients with symmetrical melasma were included in the study and were randomized to receive either fractional CO2 laser, once every 4 weeks plus TCC (group A), or TCC alone (group B) to either side of the face once daily for 12 weeks. The patients were evaluated every 4 weeks to determine treatment response and adverse effects, and were followed for another 12 weeks to determine relapse. There were 54 patients (19 male and 35 female; mean age 33.0 years, SD 7.7; age range 21–57 years). They had melasma for 0.5–15 years (mean duration 5.7 years, SD 3.5). Following treatment, the mean melanin index and modified Melasma Area and Severity Index (mMASI) scores decreased in both groups. The mean (SD) melanin index decreased from 46.5 (5.2) to 43.7 (5.6), P < 0.001, in group A, and from 47.0 (5.5) to 44.3 (5.5), P < 0.001, in group B. The mean (SD) mMASI decreased from 4.4 (1.8) to 2.8 (1.6), P < 0.001, in group A, and from 4.4 (1.9) to 3.2 (1.7), P < 0.001, in group B. The changes were statistically significant, but were comparable between the two groups (P = 0.47 and P = 0.20, respectively). However, improvement in Physician’s Global Assessment (PGA) was superior in group A vs. group B (60.8% vs. 39.1%, P < 0.001. Also, the mean (SD) patient self-assessment scores were 5.9 (2.0) and 4.6 (2.0) in group A and group B, respectively (P < 0.001) showing a better response in group A. There were no significant adverse effects. However, 67% of patients (34 of 51) had a relapse, with gradual increases in MI, mMASI, PGA and patient self-assessment scores in both groups during post-treatment follow-up. Therefore, the study has shown that fractional CO2 laser offers modest additional benefit and is safe in the treatment of melasma. Hence, further studies are required.

Fractional CO2 Lasers Contribute to the Treatment of Stable Non-Segmental Vitiligo

Investigation of Optimal Energy or Density of a Fractional CO2 Laser System in the Treatment of Stable Non-Segmental Vitiligo

Investigation of optimal energy or density of a fractional CO 2 laser system in the treatment of stable non-segmental vitiligo

Fractional CO2 Laser Versus Microneedling Combined with Narrowband Ultraviolet and Topical Steroid for Treating Non-Segmental Vitiligo in Treatment-Resistant Localizations: A Comparative Randomized Clinical Trial Study

Beneficial UVB phototherapy preceding a fractional CO2 laser-UVB protocol in refractory non-segmental vitiligo

Fractional Er:YAG Laser Assisting Topical Betamethasone Solution in Combination with NB-UVB for Resistant Non-Segmental Vitiligo

Ablative Fractional Co2 Laser Aided Delivery of Long-Acting Glucocorticoid in the Treatment of Acral Vitiligo: a Multicenter, Prospective, Self-Bilateral Controlled Study

Triple combination treatment with fractional CO2 laser plus topical betamethasone solution and narrowband ultraviolet B for refractory vitiligo: a prospective, randomized half-body, comparative study.

Clinical efficacy of CO2 fractional laser combined with compound betamethasone in treating vitiligo and its impact on inflammatory factors

Triple-combination treatment with oral α-lipoic acid, betamethasone injection, and NB-UVB for non-segmental progressive vitiligo.

Comparison of mechanical dermabrasion and CO2 laser in cultured epithelial sheets transplantation in the treatment of refractory stable vitiligo: A multicenter, prospective and self‐controlled comparative study

Comparison of mechanical dermabrasion and CO<sub>2</sub> laser in cultured epithelial sheets transplantation in the treatment of refractory stable vitiligo: A multicenter, prospective and self‐controlled comparative study

Multi-Factors Associated With Efficacy and Adverse Events of Fractional Erbium:YAG Laser-Assisted Delivery of Topical Betamethasone for Stable Vitiligo: A Retrospective Analysis

Effectiveness of fractional erbium–YAG laser, microneedling, platelet-rich plasma in localized stable vitiligo patients: randomized clinical trial

BC01 Evaluation of effectiveness of fractional ablative CO2 laser and triple combination cream in the treatment of melasma: a randomized controlled study

Randomized controlled trial of 308nm excimer laser combined with topical tacrolimus ointment in the treatment of vitiligo

Efficacy and Safety of 308 Nm Excimer Laser in the Treatment of Vitiligo

Treatment of 308-Nm Excimer Laser on Vitiligo: A Systemic Review of Randomized Controlled Trials

Efficacy of Both Autologous Epidermal Grafting and Narrow Band Ultraviolet B Radiation on Stable Vitiligo

Clinical Study of Combination Therapy of 308nm Excimer Laser and Topical Tacrolimus for Treatment of Vitiligo

Narrow-band ultraviolet B (NB-UVB) therapy in the treatment of vitiligo